Sanofi will also slash the list price of its short-acting product Apidra (insulin glulisine) by 70% from the start of next year. It hasn’t yet indicated what impact the reductions will have on ...

The growth trajectory of the Apidra market is closely linked to the rising prevalence of diabetes, which is accelerating demand for rapid-acting insulin treatments like Apidra. Diabetes ...